A clinical trial examining the effect of a cannabis-derived treatment on people with type two diabetes has produced encouraging results.
Med7 and HempCo carried out a human clinical study looking at the effect of its full spectrum hemp oil, Hempzorb81, on people with the condition.
The placebo-controlled study on 150 patients found it helped participants lose weight and lower their A1C levels, the sugar-linked haemoglobin in blood that becomes too high in people with diabetes.
Patients lost an average of 14lbs and reduced their waistlines by four inches over the course of the six month study.
The research was carried out with funding support from the National Institutes of Health, an arm of the US Department of Health.
Type two diabetes is one of the most pressing health challenges facing the world, with the number of people living with the condition continuing to rise due to obesity rates.
A 2018 report by the International Diabetes Federation found 58 million people have the condition in Europe, contributing to 477,000 deaths.
The report calculated diabetes-related health interventions cost the continent more than £126bn every year.
Paul Murray, CEO of HempCo, said: “A naturally occurring whole plant extract with multiple cannabinoids and other natural components can have strong entourage effects on cannabinoid receptors if they can get into the blood stream effectively.
“These studies should give consumers and providers confidence that there are hemp products containing CBD that are backed by human clinical studies.”
[activecampaign form=31]
